Menu Search
Equities

Aytu Biopharma Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
AY20:MUN

Aytu Biopharma Inc

Actions
  • Price (EUR)1.94
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta0.3665
Data delayed at least 15 minutes, as of Oct 31 2024 07:04 BST.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Aytu BioPharma, Inc. is a pharmaceutical company focused on advancing medicines for complex central nervous system (CNS) diseases. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.

  • Revenue in USD (TTM)62.64m
  • Net income in USD-24.56m
  • Incorporated2015
  • Employees82.00
  • Location
    Aytu Biopharma Inc7900 E. Union Avenue, Suite 920DENVER 80237United StatesUSA
  • Phone+1 (720) 437-6580
  • Fax+1 (302) 636-5454
  • Websitehttps://aytubio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.